Inhibition of rat renal fibroblast proliferation by halofuginone

Nephron - Experimental Nephrology

Volumn 104, Issue 1, 2006, Pages

  Haran, Nurit ^a   Leschinski, Ludmila ^a   Pines, Mark ^b   Rapoport, Jayson ^a,c  

^a KAPLAN MEDICAL CENTER   (Israel)

^b VOLCANI CENTER   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Fibrosis; Halofuginone; MMP 2 expression; Myofibroblasts; Papillary fibroblasts

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANTIFIBROTIC AGENT; COLLAGEN TYPE 1; COLLAGENASE; GELATIN; GELATINASE A; HALOFUGINONE; PLATELET DERIVED GROWTH FACTOR; POLYACRYLAMIDE GEL; PROLINE; TRITIUM;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FIBROBLAST; KIDNEY FIBROSIS; KIDNEY PAPILLA; MALE; MYOFIBROBLAST; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ZYMOGRAPHY;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN TYPE I; FIBROBLASTS; KIDNEY MEDULLA; MALE; MATRIX METALLOPROTEINASE 2; PIPERIDINES; PLATELET-DERIVED GROWTH FACTOR; QUINAZOLINES; QUINAZOLINONES; RATS; RATS, WISTAR;

EID: 33747226758     PISSN: 16602129     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093674     Document Type: Article

References (23)

1. Iwano M, Neilson EG: Mechanisms of tubulointerstitial fibrosis. Curr Opin Nephrol Hypertens 2004;13:279-284.
2. Liu Y: Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004;15:1-12.
3. Seppä H, Grotendorst G, Seppä S, Schiffmann E, Martin GR: Platelet-derived growth factor is chemotactic for fibroblasts. J Cell Biol 1982;92:584-588.
4. Knecht A, Fine LG, Kleinman KS, Rodemann P, Müller GA, Woo DD, Norman JT: Fibroblasts of rabbit kidney in culture. II. Paracrine stimulation of papillary fibroblasts by PDGF. Am J Physiol 1991;261(2 Pt 2): F292-F299.
5. Ruggenenti P, Schieppati A, Remuzzi G: Progression, remission, regression of chronic renal diseases. Lancet 2001;357:1601-1608.
6. Granot I, Halevy O, Hurwitz S, Pines M: Halofuginone: an inhibitor of collagen type I synthesis. Biochim Biophys Acta 1993;1156:107-112.
7. Granot I, Bartov I, Plavnik I, Wax E, Hurwitz S, Pines M: Increased skin tearing in broilers and reduced collagen synthesis in skin in vivo and in vitro in response to the coccidiostat halofuginone. Poult Sci 1991;70:1559-1563.
8. Pines M, Vlodavsky I, Nagler A: Halofuginone hydrobromide. Drugs Future1996;21:596-599.
9. Nagler A, Katz A, Aingorn H, Miao HQ, Condiotti R, Genina O, Pines M, Vlodavsky I: Inhibition of glomerular mesangial cell proliferation and extracellular matrix deposition by halofuginone. Kidney Int 1997;52:1561-1569.
10. Pines M, Knopov V, Genina O, Lavelin I, Nagler A: Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine- induced liver cirrhosis. J Hepatol 1997;27:391-398.
11. Olbrich KC, Meade R, Bruno W, Heller L, Klitzman B, Levin LS: Halofuginone inhibits collagen deposition in fibrous capsules around implants. Ann Plast Surg 2005;54:293-296.
12. Nagler A, Ohana M, Shibolet O, Shapira MY, Alper R, Vlodavsky I, Pines M, Ilan Y: Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone. Eur J Cancer 2004;40:1397-1403.
13. Yamamoto T, Nishioka K: Analysis of the effect of halofuginone on bleomycin-induced scleroderma. Rheumatology 2002;41:594-596.
14. Christner PJ, Jimenez SA: Animal models of systemic sclerosis: insights into systemic sclerosis pathogenesis and potential therapeutic approaches. Curr Opin Rheumatol 2004;16:746-752.
15. Halevy O, Nagler A, Levi-Schaffer F, Genina O, Pines M: Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone. Biochem Pharmacol 1996;52:1057-1063.
16. Rodemann HP, Müller GA, Knecht A, Norman JT, Fine LG: Fibroblasts of rabbit kidney in culture. I. Characterization and identification of cell-specific markers. Am J Physiol 1991;261(2 Pt 2):F283-F291.
17. Nagler A, Firman N, Feferman R, Cotev S, Pines M, Shoshan S: Reduction in pulmonary fibrosis in vivo by halofuginone. Am J Respir Crit Care Med 1996;154(4 Pt 1):1082-1086.
18. Elkin M, Reich R, Nagler A, Aingorn E, Pines M, De Groot N, Hochberg A, Vlodavsky I: Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone. Clin Cancer Res 1999;5:1982-1988.
19. Xavier S, Piek E, Fujii M, Javelaud D, Mauviel A, Flanders KC, Samuni AM, Felici A, Reiss M, Yarkoni S, Sowers A, Mitchell JB, Roberts AB, Russo A: Amelioration of radiation-induced fibrosis: inhibition of transforming growth factor-beta signaling by halofuginone. J Biol Chem 2004;279:15167-15176.
20. Strutz F, Zeisberg M, Ziyadeh FN, Yang CQ, Kalluri R, Müller GA, Neilson EG: Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int 2002;61:1714-1728.
21. Kliem V, Johnson RJ, Alpers CE, Yoshimura A, Couser WG, Koch KM, Floege J: Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int1996;49:666-678.
22. Ranieri E, Gesualdo L, Grandaliano G, Maiorano E, Schena FP: The role of α-smooth muscle actin and platelet-derived growth factor-beta receptor in the progression of renal damage in human IgA nephropathy. J Nephrol 2001;14:253-262.
23. Taneda S, Hudkins KL, Topouzis S, Gilbertson DG, Ophascharoensuk V, Truong L, Johnson RJ, Alpers CE: Obstructive uropathy in mice and humans: potential role for PDGF-D in the progression of tubulointerstitial injury. J Am Soc Nephrol 2003;14:2544-2555.